曲妥珠单抗
医学
心脏毒性
内科学
乳腺癌
养生
肿瘤科
佐剂
蒽环类
临床试验
癌症
辅助治疗
外科
化疗
作者
Shaohua Guo,Gary Tse,Tong Liu
出处
期刊:The Lancet
[Elsevier]
日期:2020-02-01
卷期号:395 (10223): 491-492
被引量:5
标识
DOI:10.1016/s0140-6736(19)32549-8
摘要
We read with great interest the outcomes of the PERSEPHONE trial by Helena Earl and colleagues,1 reporting less cardiotoxicity in 6-month treatment with adjuvant trastuzumab than in 12-month treatment. The cardiotoxicity of trastuzumab has been evaluated in several studies. Chang and colleagues2 summarised that 1·7–4·1% of patients treated with trastuzumab developed heart failure when anthracycline was not part of the therapeutic regimen. In the clinical setting, trastuzumab provides substantial benefit to survival and reduction of cancer recurrence in patients with HER2-positive breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI